Tin tức & Cập nhật

Faecal microbiota transplantation helps reduce abdominal bloating but not the overall symptoms in patients with irritable bowel syndrome (IBS), according to a small study.

In the phase II VELO trial, third-line (3L) treatment with the anti-EGFR* monoclonal antibody (mAb) panitumumab and standard of care (SoC) improved progression-free survival (PFS) in patients with refractory RAS wild-type metastatic colorectal cancer (WT mCRC).

Using 30 kcal/kg to predict energy requirements overestimates total energy expenditure (TEE) by 1.44 times in patients with colorectal cancer (CRC) in a controlled sedentary environment, as shown in a study. In addition, TEE is outside of the predicted requirement range for most.